Why Is Immunome Stock Soaring Monday?

Benzinga_recent_news12-16

Immunome Inc. (NASDAQ:IMNM) stock rose Monday, with session volume surging to 8.25 million shares, well above the stock’s average daily volume of 1.50 million, according to Benzinga Pro data. Immunome...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591625183?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-16 01:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591625183","market":"us","top_or_hot":-1,"title":"Why Is Immunome Stock Soaring Monday?","media":"Benzinga_recent_news","content":"<div>\n<p>Immunome Inc. (NASDAQ:IMNM) stock rose Monday, with session volume surging to 8.25 million shares, well above the stock’s average daily volume of 1.50 million, according to Benzinga Pro data.\nImmunome...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Immunome Stock Soaring Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Immunome Stock Soaring Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-16 01:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunome Inc. (NASDAQ:IMNM) stock rose Monday, with session volume surging to 8.25 million shares, well above the stock’s average daily volume of 1.50 million, according to Benzinga Pro data.\nImmunome...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","article_id":"2591625183","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591625183","pubTimestamp":1765818720,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key endpoints.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","ORR":"Militia Long/Short Equity ETF","IMNM":"Immunome Inc.","BK4139":"生物科技"},"translate_title":"为什么Immunome股票周一飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORR":1,"IMNM":1},"content_text":"Immunome Inc. (NASDAQ:IMNM) stock rose Monday, with session volume surging to 8.25 million shares, well above the stock’s average daily volume of 1.50 million, according to Benzinga Pro data.\nImmunome on Monday shared topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat for progressing desmoid tumors.\nA desmoid tumor, also known as aggressive fibromatosis, is a rare, noncancerous growth in connective tissue, often in the abdomen, arms, or legs, that is locally aggressive (infiltrates surrounding tissue) but doesn’t spread (metastasize).\nThe trial met its primary endpoint of improving progression-free survival, demonstrating a statistically significant and clinically meaningful improvement versus placebo, with an 84% reduction in the risk of disease progression or death.\nThe confirmed objective response rate (ORR) was 56% with varegacestat versus 9% with placebo.\nIn an exploratory analysis, varegacestat demonstrated a median best change in tumor volume of -83% versus +11% with placebo.\nIn addition, the trial met all key secondary endpoints, with varegacestat achieving statistically significant improvements versus placebo in landmark tumor volume reduction and worst pain intensity.\nVaregacestat was generally well-tolerated, with a manageable safety profile.\nImmunome plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second quarter of 2026.\n“RINGSIDE is the largest and most comprehensive clinical trial conducted to date in patients with desmoid tumors, and the topline results represent the highest objective response rate observed in a randomized clinical trial in this patient population,” said Immunome’s CEO, Clay Siegall, Ph.D. “These findings demonstrate the potential of varegacestat to offer best-in-class results in a convenient, once-daily, oral medicine that may help patients reclaim their lives.”\nIMNM Price Action: Immunome shares were up 20.87% at $23.65 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.\nRead Next:\nImage from Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591625183","isCrawlerRequest":true}